Key Drivers
- Strong Cash Flow
- Liquidity Decline
- Elevated Payout
AIAI Summary
QGEN is now an execution-driven turnaround rather than a pure defensive compounder: its high margins and cash flow protect downside, but upside requires CEO Pratt to convert product launches and simplification into sustained growth above the 1%–2% outlook; stay selective until revenue acceleration validates the reset, while monitoring the willful-infringement case as a material downside risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Liquidity Decline
- •Elevated Payout
QGEN delivers strong margins and cash conversion with a more moderate valuation, but weakening liquidity, higher leverage, and an unsustainably high dividend payout warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Defended support
- •Overhead resistance
- •Neutral momentum
QGEN remains range-bound over the last month, with support at $42.00–$42.50 and resistance at $44.20–$44.90; watch for a break below $42.00 or recovery above $44.20.
Declined from $44.38 to $43.33 in one session
Sentiment & News
Key News Insights:
- •New CEO
- •Platform Launch
- •Patent Verdict
Qiagen's CEO transition and QIAsymphony launch support growth momentum, but patent-infringement litigation creates material legal risk.
Growth catalysts may support QGEN sentiment, though legal exposure could weigh on investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings